Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Avelumab and Pepinemab · 1 trial · 1 indication
Measured by adverse event severity and quantity
| Arm | Type | Description |
|---|---|---|
| Experimental | EXPERIMENTAL | Single arm, all patients serially enrolled to combination doses of Avelumab and Pepinemab |
| Name | Type | Description |
|---|---|---|
| Avelumab and Pepinemab | DRUG | IV Infusions every two weeks. |
Inclusion Criteria: * Patient or legally acceptable representative must be able to understand and willing to sign an IRB approved written informed consent document. * Patients must be 18 years or older * Patients must have histologically confirmed metastatic pancreatic adenocarcinoma. * Patients mu...